PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received 'Orphan Drug Designation' by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)

by Inveready Asset Management

Palobiofarma S.L., backed by Inveready, is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of Prader-Wi...

Read more

Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team

by Inveready Asset Management

Thanks to the continued support of Inveready and Sodena, Palobiofarma has become the start-up with the broadest clinical pipeline in Spain, financed basically through licensing agreements such as the ...

Read more

Palobiofarma announces that it has been included among the 99 innovative companies in the European Innovation Council Accelerator

by SODENA

Palobiofarma has received the approval of the European project that finances Phase II of the PBF-680 product in COPD. Additionally, it offers the possibility of partial financing of Phase III of PBF-6...

Read more

Palobiofarma signs licensing agreement to develop novel adenosine-based immuno-oncology treatments

by Inveready Asset Management

Palobiofarma will receive an upfront payment of $15 million USD and is eligible to receive near-term clinical milestones and is eligible to receive development and commercial milestones on successful ...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Indexa Capital Group aumenta sus ingreso...

by Indexa Capital

Indexa Capital Group, sociedad matriz de Indexa Capital AV, Bewater As...

Photos Stream